Form 4: Chimerix Director Marc Kozin Disposes of Stock Options Following Merger with Jazz Pharmaceuticals
SEC Form 4 Filing
Director Marc Kozin reports the disposal of Chimerix stock options following the merger with Jazz Pharmaceuticals, where options were converted to cash payments.
Summary
- This Form 4 filing reports changes in beneficial ownership for Marc D. Kozin, a director of Chimerix, Inc.
- The filing is triggered by the merger between Chimerix and Jazz Pharmaceuticals, which became effective on April 21, 2025.
- As a result of the merger, Kozin's employee stock options were affected.
- Specifically, 'in the money' options (exercise price less than the offer price of $8.55 per share) were accelerated, fully vested, and then cancelled.
- These cancelled options were converted into the right to receive a cash payment based on the difference between the offer price and the exercise price, multiplied by the number of shares subject to the option.
- Kozin disposed of 100,000 options with an exercise price of $0.99 and 60,000 options with an exercise price of $0.89.
- Following the reported transactions, Kozin holds zero derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it primarily reports a transaction related to a previously announced merger. The director's actions are a consequence of the merger agreement.
Future Outlook
The document does not contain any specific forward-looking statements beyond the completion of the merger.
Industry Context
This announcement reflects the completion of a merger in the pharmaceutical industry, where acquisitions are common for companies looking to expand their product portfolios or pipelines. Jazz Pharmaceuticals acquired Chimerix.
Stakeholder Impact
- Shareholders received $8.55 per share as part of the merger agreement.
- Option holders with 'in the money' options received a cash payment based on the difference between the offer price and the exercise price.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of the Agreement and Plan of Merger between Chimerix, Jazz Pharmaceuticals, and Pinetree Acquisition Sub, Inc. |
| 04/17/2025 | Expiration date of the tender offer for all outstanding shares of Chimerix common stock. |
| 04/21/2025 | Effective date of the merger between Purchaser and Chimerix. |
| 04/21/2025 | Date of the reported transaction (disposal of stock options). |
| 03/19/2034 | Expiration date of one set of employee stock options. |
| 06/19/2034 | Expiration date of another set of employee stock options. |
Keywords
Form 4, Chimerix, Jazz Pharmaceuticals, Merger, Stock Options, Beneficial Ownership, Kozin, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.